Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Increasing complex I stability as a cure for mitochondrial diseases

Project description

Complex I as a critical target in curing mitochondrial diseases

Mitochondria are cell energy hubs, generating the majority of cellular adenosine 5′-triphosphate (ATP) via a respiratory chain coupled to oxidative phosphorylation. The oxidation of nicotinamide adenine dinucleotide + hydrogen (NADH) by the enzyme NADH:ubiquinone oxidoreductase (Complex I) provides the main driving force for ATP synthesis. Complex I deficiency is the most common pathology in mitochondrial diseases, Parkinsonism, diabetes, cancer and ageing. Preliminary data have demonstrated that stabilisation of Complex I could ameliorate the symptoms of respiratory deficiency in cellular models of mitochondrial dysfunction, and this stabilisation could be achieved with the loss of caseinolytic peptidase. The EU-funded CICURE project aims to investigate the possibility of targeting caseinolytic peptidase located in the mitochondrial matrix to ameliorate symptoms of mitochondrial diseases using in vivo genetic models.

Objective

Mitochondria are found within every human cell and are responsible for the majority of energy production in the cell. When the mitochondria do not function properly, they cause devastating diseases affecting many and often multiple organs with the highest energy needs, such as skeletal muscle, brain, heart and liver. Over the years we have steadily increased our understanding of the genetic and molecular mechanisms leading to mitochondrial disease, developed different models and biomarkers. Unfortunately, development of effective therapeutic approaches able to improve the outcome of the diseases or at least to ameliorate or postpone the symptoms was much less effective.
Today, therapeutic options for mitochondrial diseases still remain focused on supportive dietary interventions aimed at relieving complications. Therefore, it would be ideal if a single approach could be developed that would be equally effective with various mitochondrial diseases most often characterized by complex I deficiency.
Our preliminary data show that by removing the major mitochondrial matrix protease CLPXP, and therefore stabilizing CI, we could ameliorate the symptoms of respiratory deficiency in different cellular models of mitochondrial dysfunction. The loss of CLPP in these models resulted not only in increased stability of CI, but also normalized NAD+/ NADH that collectively resulted in improved proliferation and survival rates. Remarkably, even partial loss of ClpXP activity in respiratory deficient cells led to mild increase in the CI levels, opening an exciting prospect for therapeutic interventions. Therefore, the overall goal of this project is to explore the possibility of targeting CLPP activity to ameliorate symptoms of mitochondrial diseases in in vivo models through genetic interventions and search for specific protease inhibitors.

Fields of science (EuroSciVoc)

This project has not yet been classified with EuroSciVoc.
Be the first one to suggest relevant scientific fields and help us improve our classification service

Keywords

Programme(s)

Topic(s)

Funding Scheme

ERC-POC - Proof of Concept Grant

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2018-PoC

See all projects funded under this call

Host institution

KLINIKUM DER UNIVERSITAET ZU KOELN
Net EU contribution
€ 150 000,00
Address
Kerpener Strasse 62
50937 Koeln
Germany
Region
Nordrhein-Westfalen Köln Köln, Kreisfreie Stadt
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 150 000,00

Beneficiaries (1)